Tagged with PR

Europe Writing in the August edition of DIA’s Global Forum, Sanofi R&D’s Thomas Kühler outlines the bumpy journey towards the full adoption of Health Technology Assessment (HTA) across Europe.   More than three years ago, in January 2018, the European Commission published a draft Regulation on Health Technology Assessment for the EU.…

Italy In recent months, a profound transformation has been occurring right at the core of the Italian pharmaceutical industry as the most significant reforms to market access within two decades start to take shape. While Mario Draghi’s energetic government has been dominating the headlines primarily for other reasons – namely sweeping…

Singapore Industry veteran Marine Queniart-Stojanovic, a self-described “global citizen with a French passport,” currently serves as Sanofi’s GM for general medicines in Thailand, Malaysia, and Singapore. With Sanofi undergoing a significant transformation in its business approach, Queniart-Stojanovic is adapting this to the market realities in her managed countries as well as…

Turkey Almost two decades after initiating large-scale health system reforms, Turkey has consolidated the provision of universal healthcare coverage to over 95 percent of the population. The effort, part of the country’s Health Transformation Program introduced in 2003, has been commended by international organizations across the world. But today, as citizens…

Turkey After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to her country by improving patients’ access to life-saving therapies.   For Russ, what began as a consultant role at McKinsey…

Saudi Arabia As part of Saudi Arabia’s ambitious ‘Vision 2030’ economic transformation plan, the country has centralised the public procurement of medications through the National Unified Procurement Company for Medical Supplies (NUPCO). Here, some of the Kingdom’s most prominent pharma leaders weigh in on the impact of this new system for their…

Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a specialty pharma player focused on the digestive system, has overseen a number of acquisitions and the growth of the company from 30 to 300 employees. Here, he shares his insights on why M&A may be a better strategy…

Switzerland While once considered the land of milk and honey within Europe in terms of market access and reimbursement for innovative pharmaceuticals, Switzerland is increasingly tightening its belt on this front in line with its European neighbours. Indeed, this year two cost containment packages are under discussion in the Swiss parliament…

China Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach differs from that of its competitors, and how he plans to make the firm into “China’s Genentech.”   We want…

Global Merck VP for Global Market Access & Pricing Strategic Planning Marco Rauland outlines how AI has already begun to transform pharmaceutical strategy and highlights five ways in which it can be better utilised in pricing and market access decision making.   Artificial intelligence (AI) has been creating a buzz in…

China Genetron Health is a publicly-traded China-based precision oncology company, covering the “full-cycle” of cancer care, from early screening, diagnosis, and treatment recommendations to continuous monitoring care. CEO and Co-Founder Sizhen Wang explains how the company obtained US FDA Breakthrough Device Designation, analyzes the Chinese biotech sector, and highlights their objective…

Korea The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown blockbuster drug; Prestige Biopharma’s move to open a vaccine facility; and Samsung Bioepis’ first steps into the Australian market.   ‘Now is best time to develop Korean blockbuster drug’ (Korea Biomedical…